Concepedia

R. Just

RJ

Statistics

Publications

5

Citations

221

H-Index

5

Active since

2006

Affiliations

University of California, Los Angeles(Current)

R. Just is an author at University of California, Los Angeles specializing in medicine, pharmacology, and cancer pharmacology.

Publications per year

2006–2012

5

Publications

5

Phase II Trial of Idiotype Vaccination in Previously Treated Patients With Indolent Non-Hodgkin’s Lymphoma Resulting in Durable Clinical Responses

Charles H. Redfern, Troy H. Guthrie, Alberto Bessudo et al. · Journal of Clinical Oncology · 2006 · 89 citations

Medicine, Hematology, Immunology +16

Phase 1 dose‐escalation trial evaluating the combination of the selective MET (mesenchymal‐epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib

Jonathan W. Goldman, Isett Laux, Ronald E. Savage et al. · Cancer · 2012 · 77 citations · Full text

Medicine, Oncology, Pharmacology +15

Phase I dose escalation trial (ARQ 197–111) evaluating combination of selective c-Met inhibitor ARQ 197 and erlotinib

Isett Laux, J M Goldman, R. Just et al. · Journal of Clinical Oncology · 2009 · 24 citations

Medicine, Oncology, Pharmacology +15

A phase I dose escalation and pharmacokinetic (PK) study of intravenous (iv) aflibercept (VEGF Trap) plus FOLFOX4 in patients (pts) with advanced solid tumors: Preliminary results

Steven Limentani, R. Just, A. Purdham et al. · Journal of Clinical Oncology · 2008 · 18 citations

Pharmacy, Oncology, Pharmacology +17

A phase I study of sonepcizumab (S), a humanized monoclonal antibody to sphingosine-1-phosphate (S1P), in patients with advanced solid tumors.

Michael S. Gordon, R. Just, Lee S. Rosen et al. · Journal of Clinical Oncology · 2010 · 13 citations

Medicine, Clinical Pharmacokinetics, Pharmacology +17

1–5 of 5